# Synthesis, Characterization, and Cytotoxicity of Dicyclo­alkyl­amine­pyrophosphato­platinum​(II) Complexes

## TL;DR

This paper introduces two new platinum-based compounds and tests their effects on cancer cells to improve chemotherapy options.

## Contribution

The study synthesizes and evaluates two new dicycloalkylaminepyrophosphatoplatinum(II) complexes for potential cancer treatment.

## Key findings

- The new compounds show reduced cell viability in human lung and breast cancer cell lines.
- They inhibit cell viability less than the leading phosphaplatin drug candidate.
- The work contributes to understanding structure-activity relationships in phosphaplatins.

## Abstract

Platinum complexes have now been used in chemotherapy
regimens
for almost half a century to treat a variety of cancers. The most
clinically significant of these compounds to date is cisplatin, cis-di­ammine­dichloro­platinum­(II), whose
clinical application has significantly reduced the mortality rate
of several cancers. Despite this development, there is still a push
to find new compounds that have improved efficacy, that can be administered
at lower doses, and that produce less severe side-effects compared
to current options. One class of molecules that may fill that role
is phosphaplatins, an underexplored class of platinum­(II) complexes
that contain a bidentate pyrophosphate ligand. These compounds are
anionic at physiological pH and display reduced DNA-binding compared
to cisplatin. This study expands on the list of known phosphaplatins
by introducing two new compounds, di­cyclo­butyl­amine­dihydrogen­pyro­phosphato­platinum­(II)
and dicyclo­pentylamine­dihydrogen­pyrophosphato­platinum­(II).
Here we report complete synthetic details, as well as cell viability
data in response to these compounds using two cancer cell lines, a
human lung adenocarcinoma and a triple-negative human breast cancer.
While these compounds inhibit cell viability less than the leading
phosphaplatin drug candidate, trans-(1R,2R)-diamino­cyclo­hexane­dihydrogen­pyro­phosphato­platinum­(II),
this work represents an important step in elucidating structure–activity
relationships for this class of molecules.